Additional chromosome aberrations in acute promyelocytic leukemia: characteristics and prognostic influence
- PMID: 11114710
- DOI: 10.1007/BF02782196
Additional chromosome aberrations in acute promyelocytic leukemia: characteristics and prognostic influence
Abstract
Patients with acute promyelocytic leukemia (APL) show other chromosome aberrations in addition to t(15;17) but their influence on the clinical outcome is still unclear. We have cytogeneticaly analyzed 43 APL patients with t(15;17)(q22;q21), treated with all-trans-retinoic acid (ATRA) according to the recommendations of the European APL 91 Group. Additional chromosome aberrations were observed in 14/43 patients (33%) studied at initial diagnosis. These patients were designed as 'complex' karyotype group and were compared to patients with t(15;17) asa sole cytogenetic abnormality ('simple' karyotype group). The 'complex' group had significantly lower platelet count and fibrinogen level and fewer cases without significant DIC at diagnosis than the 'simple' group. Comparison of 'simple' and 'complex' groups showed significant difference in complete remission rate (76% vs 35.7%, P = 0.0148) and early death rate (24% vs 64.3%, P = 0.0141). Survival analysis showed that the presence of additional chromosome abnormalities and significant DIC had an adverse effects on prognosis (P = 0.036 and P = 0.041, respectively), independent on other prognostic factors. These data indicate more aggressive biological nature of leukemic cells in patients with additional chromosome aberrations. Supplementary therapeutic strategies may be required for this subgroup of APL patients.
Similar articles
-
Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.Haematologica. 2010 Mar;95(3):424-31. doi: 10.3324/haematol.2009.013243. Epub 2009 Nov 10. Haematologica. 2010. PMID: 19903674 Free PMC article.
-
Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial.Br J Haematol. 2000 Dec;111(3):801-6. doi: 10.1046/j.1365-2141.2000.02442.x. Br J Haematol. 2000. PMID: 11122141 Clinical Trial.
-
Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.Leuk Res. 2013 Nov;37(11):1451-6. doi: 10.1016/j.leukres.2013.07.030. Epub 2013 Aug 16. Leuk Res. 2013. PMID: 23958062 Clinical Trial.
-
Trisomy 21 and other chromosomal abnormalities in acute promyelocytic leukemia.Cancer Genet Cytogenet. 2003 Jan 15;140(2):170-3. doi: 10.1016/s0165-4608(02)00684-2. Cancer Genet Cytogenet. 2003. PMID: 12645658 Review.
-
Acute promyelocytic leukemia: from clinic to molecular biology.Stem Cells. 1995 Jan;13(1):22-31. doi: 10.1002/stem.5530130104. Stem Cells. 1995. PMID: 7719245 Review.
Cited by
-
Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17).Med Oncol. 2012 Sep;29(3):2095-101. doi: 10.1007/s12032-012-0251-7. Epub 2012 May 22. Med Oncol. 2012. PMID: 22729365 Free PMC article.
-
A review of arsenic trioxide and acute promyelocytic leukemia.Int J Hematol Oncol Stem Cell Res. 2014 Jul 1;8(3):44-54. Int J Hematol Oncol Stem Cell Res. 2014. PMID: 25642308 Free PMC article. Review.
-
Co-expression of t(15;17) and t(8;21) in a Case of Acute Promyelocytic Leukemia: Review of the Literature.Turk J Haematol. 2013 Dec;30(4):400-4. doi: 10.4274/Tjh.2012.0180. Epub 2013 Dec 5. Turk J Haematol. 2013. PMID: 24385831 Free PMC article.
-
Trisomy 11 as an additional chromosome alteration in a child with acute promyelocytic leukemia with poor prognosis.Case Rep Genet. 2012;2012:659016. doi: 10.1155/2012/659016. Epub 2012 Jul 5. Case Rep Genet. 2012. PMID: 23074691 Free PMC article.
-
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study.Haematologica. 2021 Dec 1;106(12):3100-3106. doi: 10.3324/haematol.2021.278722. Haematologica. 2021. PMID: 34047178 Free PMC article.